Belite Bio, Inc. Sponsored ADR BLTE
167.33
(2.11)
(1.25%)
as of 25 Sep
- Market cap
- $6.8B
- P/E
- 0.0×
Follow BLTE
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Current Ratio |
26.41 | 10.66 | 20.35 | 24.76 | 24.31 | 50.02 |
Net Debt/EBITDA |
4.47 | 1.78 | 3.33 | 2.82 | 3.67 | 5.88 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.77 | 0.77 | 0.91 | 0.94 | 0.81 | 0.48 |
Capex/Depreciation |
(1.18) | (1.87) | (1.99) | (0.16) | (0.34) | (0.38) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 87.36% | (95.79%) | (47.95%) | (30.60%) | (16.94%) | |
| 0.00% | (43.85%) | (40.40%) | (45.54%) | (29.29%) | (16.64%) | |
ROIC |
0.00% | 0.00% | 0.00% | (870.38%) | (3,719.87%) | (18.93%) |
Return on Tangible Assets |
(23.25%) | (60.83%) | (30.67%) | (36.44%) | (25.55%) | (16.01%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.51) | (0.79) | (0.59) | (1.12) | (0.96) | (1.11) |
Cash per Share |
2.91 | 1.81 | 2.11 | 3.31 | 4.75 | 14.68 |
Shareholders Equity per Share |
(0.80) | (1.58) | 2.08 | 3.40 | 4.78 | 22.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.80) | (1.58) | 2.08 | 3.40 | 4.78 | 22.97 |
Free Cash Flow |
(4.46) | (7.53) | (11.85) | (29.90) | (29.38) | (37.17) |
Working Capital |
24.70 | 15.80 | 40.70 | 86.31 | 141.02 | 484.39 |
Capital Expenditures |
(0.02) | (0.06) | (0.39) | (0.06) | (0.15) | (0.18) |
Net Current Asset Value |
(7.11) | (16.01) | 40.04 | 85.73 | 140.76 | 484.20 |
| Other line items | ||||||
Quick Ratio |
26.40 | 10.62 | 20.01 | 24.50 | 24.09 | 49.90 |
Depreciation/Fixed assets |
0.37 | 0.32 | 0.37 | 0.81 | 1.01 | 1.35 |
Cash ROIC |
(24.15%) | (336.21%) | (14.35%) | (16.98%) | (10.20%) | (2.96%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | — | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.51) | (0.78) | (0.57) | (1.12) | (0.96) | (1.10) |
Capex per Share |
0.00 | (0.01) | (0.02) | 0.00 | 0.00 | (0.01) |
Average Receivables |
— | 0.03 | 0.01 | 0.42 | 0.71 | 0.64 |
Average Assets |
— | 22.04 | 31.31 | 69.46 | 123.39 | 466.34 |
Average Common Equity |
— | (11.06) | 13.20 | 65.97 | 118.13 | 458.15 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates